Skip to Main Content
American Flag
LABOR DAY SALE

50% off your first year of any Quiver subscription

...

Use Promo Code:

LABOR26
American Flag
×
Quiver Logo Get a Free Trial on Quiver Premium Today!
Back to News

Cingulate Reports $7.7 Million Third-Quarter Loss, Targets CTx-1301 NDA Resubmission

None

Cingulate Inc. (NASDAQ: CING) reported a net loss of $7.7 million for the third quarter ended September 30, 2026, compared with a $7.3 million loss a year earlier. The company reported $23.2 million in cash and cash equivalents at quarter-end.

Cingulate said it has substantially completed manufacturing work addressing FDA chemistry, manufacturing and controls requests for CTx-1301 and expects to resubmit its new drug application between December 2026 and January 2027.

  • Third-quarter research and development expense was $2.9 million, up 2.2% from the prior-year period.
  • Third-quarter selling, general and administrative expense was $4.6 million, up 45.5% year over year.
  • Net loss for the first nine months of 2026 was $22.9 million, versus $16.2 million in the prior-year period.
  • Working capital was approximately $18.8 million as of September 30, 2026.
  • The company said its cash and cash equivalents are expected to fund operations into mid-2027 under its current business plan.
EARLY ACCESS
Receive CINGW Data Alerts
Real-time alerts on filings, insider trades, and market signals — before everyone else.
Get Alerts →

$CINGW Hedge Fund Activity

We have seen 6 institutional investors add shares of $CINGW stock to their portfolio, and 0 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

Add Quiver Quantitative to your preferred sources on Google Google News Logo

Suggested Articles